pharma · Allergies · Early Parkinson Disease
Advanced Accelerator Applications
Advanced Accelerator Applications clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 20 rue Diesel, Saint Genis Pouilly, 01630, FR, RUEIL-MALMAISON
- Employees
- 590
- Programs
- 12
- Drugs
- 25
- Patents
- 25
Advanced Accelerator Applications projects
7 ClinicalTrials.gov programs sponsored by Advanced Accelerator Applications.
Advanced Accelerator Applications has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
API-EAD-2024-01
Advanced Accelerator Applications
Allergies
1 trial -
API-EAL-2024-01
Advanced Accelerator Applications
Allergies
1 trial -
APISLIT-DD-D-2025-01
Advanced Accelerator Applications
Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy
1 trial -
CAAA601A32201
Advanced Accelerator Applications
somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas
1 trial -
K0706
Advanced Accelerator Applications
Early Parkinson Disease
1 trial -
Vodobatinib (K0706) capsules
Advanced Accelerator Applications
Healthy (For Part A)
1 trial -
[177Lu]-NeoB solution for infusion, AAA503
Advanced Accelerator Applications
Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake.
1 trial
Frequently asked questions
How many clinical projects does Advanced Accelerator Applications have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.